Our sisten company, hameln pharma, is now also offering WFI and buffered solutions in bags. Manufactured and filled in compliance with GMP regulations these solutions are suitable for processes from API development, to clinical studies phase I up to market supply.

For more information please see here.

The EU guideline REACH requires a licensing procedure for substances of very high concern (SVHC) when their percentage in a product amounts to more than 0.1%. As hameln rds has been conducting analyses according to REACH since the guideline was implemented in 2007 it has comprehensive knowledge about REACH requirements and is also able to conduct analyses on SVHC.

You can find more news articles in our archive.